title: Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
abstract: BACKGROUND
  Chordomas are very rare low-grade malignant bone tumors that arise from the embryonic rests of the notochord. They are characterized by slow growth and long history with frequent local relapses, and sometimes metastases. While chemotherapy is not efficient, imatinib has shown antitumor activity.
  
  
  METHODS
  We report on a 76-year-old patient with EGFR-overexpressing advanced chordoma that progressed on imatinib and subsequently responded to erlotinib during 12 months.
  
  
  CONCLUSIONS
  We report the fourth case of advanced chordoma treated with an EGFR inhibitor. We also review the literature concerning the rationale and potential of EGFR targeting in chordoma.
authors.affiliation: Department of Medical Oncology, Institut Paoli-Calmettes, 232 bd Ste-Marguerite, Marseille, 13009, France.
authors.forename: Simon G
authors.initials: SG
authors.lastname: Launay
authors.forename: Bruno
authors.initials: B
authors.lastname: Chetaille
authors.forename: Fanny
authors.initials: F
authors.lastname: Medina
authors.forename: Delphine
authors.initials: D
authors.lastname: Perrot
authors.forename: Serge
authors.initials: S
authors.lastname: Nazarian
authors.forename: Jérôme
authors.initials: J
authors.lastname: Guiramand
authors.forename: Laurence
authors.initials: L
authors.lastname: Moureau-Zabotto
authors.forename: François
authors.initials: F
authors.lastname: Bertucci
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002817:Chordoma / Q000188:drug therapy* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011799:Quinazolines; D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors